ABSTRACT
INTRODUCTION
In 2012, the number of new cases of cervical cancer (CC) was 527,600, whereas the number of deaths due to this disease reached 265,700. CC has become the second most frequently diagnosed tumor and the third leading cause of malignant deaths among women in developing countries [1] . In China, an increasing prevalence of CC was found in young patients [2, 3] .
Novel therapeutic strategies to treat CC have undergone significant development, but the overall efficiency of these strategies remains poor. This outcome can be attributed to the capability of tumor cells to escape from the host immune surveillance. Evasion of immune destruction has become a newly-discovered hallmark of cancer [4] . Hence, understanding the mechanism underlying tumor immune escape is important for fabricating novel immunotherapeutic approaches.
During cancer progression, regulatory T (Treg) cells dynamically contribute to establish the immune suppressive condition, which to a large extent hampers anti-tumor immune responses. High Treg cell frequency is closely related to poor prognosis in various tumors, such as breast cancer, renal cell carcinoma, nonsmall cell lung cancer, and pancreatic ductal cancer. Accumulating evidence suggests that Tregs are made up of heterogeneous subpopulations. Aside from the well-known surface markers CD4 and CD25, biomarkers foxhead box P3 (FoxP3), CD127 low , CD39, CD73, glycoprotein A repetitions predominant, and cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) also comprise the functional subpopulations of Treg cells [5] [6] [7] [8] . Diversity of the Treg markers is associated with the functional characteristics.
Tumor necrosis factor receptor 2(TNFR2), combined with the simultaneous expression of CD4 and CD25, identifies the maximally suppressive subgroups of Tregs in both mice and human beings [9, 10] . Moreover, TNFR2 is involved in the homogeneous expansion of Tregs, rendering it a potential target for manipulating Tregs in the treatment of various diseases [11] . However, to the best of our knowledge, the role of TNFR2 Tregs was markedly higher in the peripheral total CD4 cells of patients with CC (median=7.12%, range, 3.25-13.16%, P<0.001) and CIN (median=5.97%, range, 3.11-9.16%, P<0.001) than in those of healthy controls (median=4.49%, range, 1.66-7.34%). A similar increasing trend was also detected between patients with CC and patients with CIN (P=0.001) (Figure 2A) . Furthermore, the proportion of TNFR2 + Tregs was higher in patients with CC (median=4.07%, range, 1.78-9.16%, P<0.001) and CIN (median=3.54%, range, 1.55-6.28%, P<0.001) than in healthy controls (median=2.40%, range, 0.47-4.57%). In addition, the level of peripheral TNFR2 + Tregs was higher in patients with CC compared with that in patients with CIN (P=0.013) ( Figure 2B ).
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We further compared the level of TNFR2 + Tregs between tumor infiltrating lymphocytes (TILs) and peripheral blood (PB) from 12 patients with CC. A typical flow cytometry result of representative CC patient was shown in Figure 3A- Figure 3G ).
Plasma concentrations of soluble TNFR1(s-TNFR1) and soluble TNFR2(s-TNFR2) increased in patients with CC
The plasma levels of s-TNFR1 and s-TNFR2 in patients with CC and in healthy controls were determined by enzyme-linked immunosorbent assay (ELISA). As shown in Figure 4A , patients with CC (median=843.4pg/ mL; range, 434.9-2087.6pg/mL, n=51, P=0.011) displayed higher levels of s-TNFR1 compared with healthy controls (median=718.0pg/mL; range, 369.9-1045.3pg/mL, n=25). A similar increase was observed in the concentration of s-TNFR2 in patients with CC (median=1917.8pg/mL; range, 983.1-3317.1pg/mL, n=51, P=0.046) compared with healthy controls (median=1817.2pg/mL; range 1051.2-2924.4pg/mL, n=25) ( Figure 4B ).
Expression levels of TNF-α, TNFR1, TNFR2, and FoxP3 in patients with CC, patients with CIN, and in healthy controls
Patients with CC (median=0.0098, range, 0.0027-0.0413) showed significantly higher mRNA expression levels of tumor necrosis factor α (TNF-α) than patients with CIN (median=0.0057, range, 0.0020-0.0224, P=0.009) or healthy controls (median=0.0043, range, 0.0006-0.0176, P<0.0001). Nonetheless, no significant difference was found between patients with CIN and healthy controls (P>0.05) ( Figure 5A ).
No statistical difference in TNFR1 expression was observed among patients with CC (median=0.0045, range, 0.0010-0.0135), patients with CIN (median=0.0034, range, 0.0008-0.0090) and healthy controls (median=0.0037, range, 0.0007-0.0076)(P>0.05) ( Figure 5B ). By contrast, the mRNA expression of TNFR2 was significantly higher in patients with CC (median=0.0084, range, 0.0024-0.0276) than in patients with CIN (median=0.0046, range, 0.0018-0.0135, P<0.001) and healthy controls (median=0.0063, range, 0.0023-0.0121, P=0.010), respectively. However, patients with CIN and healthy controls showed no statistical difference in the mRNA expression of TNFR2 (P>0.05) ( Figure 5C ).
The expression level of Foxp3 was much higher in patients with CC (median=0.00045, range, 0.00003-0.00198, P<0.001) and patients with CIN (median=0.00050, range, 0.00006-0.00403, P<0.001) compared with healthy controls (median=0.00014, range, 0.00003-0.00122), but no significant difference was found between CC patients and CIN patients (P>0.05) ( Figure  5D ). Furthermore, patients with stage II CC showed higher plasma levels of s-TNFR1(median=879.0pg/ mL; range, 517. .4pg/mL) and s-TNFR2(median=1973.7pg/mL; range, 1440.3-3211.2pg/ mL) compared with patients with stage I CC (s-TNFR1: median=799.4pg/mL, range, 434.9-2087.6pg/mL; s-TNFR2: median=1919.9pg/mL, range 983.1-3317.1pg/ mL), but the difference was not significant (P>0.05).
Correlation among circulating TNFR2
DISCUSSION
TNFR2 is a transmembrane receptor that can bind to TNF-α, a pleiotropic cytokine involved in regulating the tumor microenvironment [12] . TNFR1 is ubiquitously expressed, whereas TNFR2 is expressed mainly on immune cells and endothelial cells under most physiological circumstances [13] . Transmembrane TNF-α (mTNF) and soluble TNF-α activate TNFR1, whereas TNFR2 is effectively activated mainly by combining with mTNF [14] . TNFR2 preponderantly expressed by Tregs is involved in TNF-α boosted Treg activation, expansion, and homeostasis [15] [16] [17] . Contrary to an immunoprotective role in autoimmune pathogenesis, the immunosuppression triggered by Tregs could be detrimental to effective anticancer immune responses [18] .
In the current study, we examined the frequency of TNFR2 Tregs is correlated with highly immunosuppressive microenvironment in malignant diseases, such as acute myeloid leukemia (AML) [19] , lung cancer [20] , and ovarian cancer [21] , as well as in autoimmune disorders including type 1 diabetes and rheumatoid arthritis [22, 23] . Ex vivo experiments also demonstrated a novel regulatory role of TNFR2 on Treg cell function and expansion [24] [25] [26] [16, 30] . Hence, we hypothesize that the peripheral immunosuppressive environment favors a Treg increment at the initial stage of CC. As the disease progressed, activation and proliferation of Teff were poorly restrained by the expanding Tregs; consequently, Teff performed a depressing ability to boost Treg. Thus, a slightly lower proportion of TNFR2 + Tregs in stage II was observed in our study. To confirm our hypothesis, further research on the distribution of related effector T cell subsets is needed.
TNFRs also appear in circulating forms, which are mainly generated by shedding from extracellular parts of membrane-bound TNFR by TNF-α-converting enzyme or alternative splicing of receptor transcripts [31] . Soluble TNFRs may act as antagonists for TNF-α or compete with their membrane-anchored counterparts for the ligand, thus neutralizing its proinflammatory and anti-proliferative activities [32, 33] . Conversely, at low concentrations and under certain circumstances, combining with soluble receptors could serve as a mechanism for stabilizing TNF-α and represents a reservoir for the slow-release of TNF-α [34] . Elevated s-TNFR levels and disease progression are correlated in various cases, such as inflammatory bowel disease, colorectal cancer, and chronic kidney disease [35] [36] [37] . Accordingly, we observed higher levels of both peripheral s-TNFR1 and s-TNFR2 in patients with CC compared with healthy controls. Enhanced s-TNFR levels possibly provide regulatory effects in response to increasing TNF-α concentration in various solid tumors, including CC.
We further examined the mRNA expression levels of FoxP3, TNF-α, TNFR1, and TNFR2 in PBMCs to determine whether similar changes occur at the transcriptional level in patients with CC. Our results showed that the mRNA levels of FoxP3, TNF-α, and TNFR2 were significantly higher in patients with CC than in healthy controls, whereas TNFR1 did not show a similar trend. However, we could not exclude the possibility for the differential expression of TNFR1, given its ubiquity. Further studies are needed to investigate gene expression in different subsets of CD4 + T cells. FoxP3, a major transcription factor for Tregs, plays a vital role in establishing Treg phenotype and promoting their development [38] . In line with a previous report that the expression and shedding of TNFR2 share the same signals [39] , upregulated expression of TNFR2 on Tregs and soluble TNFR2 was detected in the present work. Hence, we hypothesize that elevated gene expression is a driving force contributing to the growing population of TNFR2 + Tregs and soluble TNF-α receptors. 
MATERIALS AND METHODS
Patients and healthy volunteers
We enrolled and monitored 72 first-time admitted patients with CC (median age: 47. 
Flow cytometric analysis of TNFR2
+ Treg cells 5 ml of peripheral blood from every subject was collected in heparin-coated tubes before any treatments had done. PBMCs were isolated by Ficoll-Paque combined with density gradient centrifugation. In brief, peripheral blood was diluted with an equal volume of 0.9% saline and mix thoroughly. The diluted blood sample was then carefully layered onto the Ficoll-Paque media solution. After centrifugation at 400×g for 20 min, the mononuclear cell layer at the interface was gently collected and washed twice with 0.9% saline.
Tumor lesions were collected immediately after resection during the surgery and washed with phosphatebuffered saline (PBS) to remove the blood on the surface. Then tissues were cut into 1mm 3 fragments and incubated with collagenase -IV, hyaluronidase, and DNAse type IV (Sigma) at 37°C for 2 hours. After digestion the mixture was filtrated through a 200 mesh cooper filter to make the single-cell suspension. Tumor infiltrating lymphocytes (TILs) were purified by density gradient centrifugation. The PBMCs and TILs were prepared for flow cytometry using the following procedures.
PBMCs and TILs were re-suspended and incubated at 4 °C in the dark for 30 min with a mixture of the following monoclonal antibodies: FITC-conjugated anti-human CD4 (BioLegend, San Diego, CA, USA), PerCP/cy5.5-conjugated anti-human CD25 (BioLegend, San Diego, CA, USA), and APC-conjugated antihuman TNFR2 (R&D Systems Inc., Minneapolis, MN, USA). Simultaneously, isotype controls were established to correct the compensation and to confirm antibody specificity. Then, we washed the mixture and re-suspended the stained cells by adding 300μL of PBS before performing flow cytometry acquisition on a BD FACSCalibur™ flow cytometer. Data were analyzed using Flowjo 7. 
Determination of s-TNFR levels by ELISA
Immediately after blood was drawn, plasma specimens were obtained by centrifugation and stored at −80 °C for further assay. Plasma s-TNFR1 and s-TNFR2 levels were measured by ELISA in accordance with the manufacturer's instructions (R&D Systems Inc., Minneapolis, MN, USA). All samples were examined in duplicate. Standard curves were drawn to calculate the concentrations. The sensitivities of detection were as follows, s-TNFR1, 1.2pg/mL; s-TNFR2, 2.3pg/mL.
Quantitative real-time polymerase chain reaction analysis
Total RNA was isolated from PBMCs by TRIzol reagent (Takara Bio Inc., China) in accordance with the manufacturer's recommendations. The purity of RNA solution was evaluated by the ratio of the absorbance at 260 and 280 nm using a spectrophotometer (Implen, P330-31). Samples with a ratio between 1.8 and 2.0 were eligible for our study. In total, 1μg of RNA was converted into complementary DNA (cDNA) using a Prime Script RT reagent Kit (Takara Bio Inc., China). Reverse transcription reaction was performed at 37 °C for 15 min, followed by 85 °C for 5 s. Real-time polymerase chain reaction (PCR) was performed on a Roche Applied Science LightCycler®480II Real-time PCR system (Roche Applied Science, USA) in accordance with the manufacturer's instructions. The PCR reactive system, including 5 μL of 2×SYBR Green Real-time PCR Master Mix, 3.2 μL of ddH 2 O, 1 μL of cDNA, 0.4 μL of the forward primers, and an equal volume of reverse primers, reached a final volume of 10 μL. The primer sequences are shown in Table 2 . All samples were examined in triplicate. The PCR products were analyzed by melt curve analysis and agarose gel electrophoresis to estimate product size and to ensure that no by-products were formed. Gene expression was normalized to a housekeeping gene (β-actin) for relative quantification.
Statistical analysis
Data distribution was analyzed by KolmogorovSmirnov test (K-S test). Results were presented as median (range). Mann-Whitney U test and Kruskal-Wallis test were used to assess statistical differences among nonnormal distributed data. All tests were performed using SPSS 21 software. Statistical significance was considered at P<0.05. 
